New drug combo aims to knock out tough blood cancers
NCT ID NCT07153497
Summary
This study is testing if adding a new drug called olutasidenib to standard treatments helps patients with certain blood cancers. It is for adults newly diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have a specific genetic change called an IDH1 mutation. The goal is to see if the combination leads to deeper, longer-lasting remission and reduces the need for blood transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.